SCHEMBL3280304

SCHEMBL3280304

Cc1ccc(S(=O)(=O)n2ccc3c(Nc4ccc5cn[nH]c5c4)nc(Nc4ccc(S(N)(=O)=O)cc4)nc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.43
JAK1 P23458 2/20 0.42
JAK3 P52333 2/20 0.42
PDGFRB P09619 7/20 0.41
PDGFRA P16234 7/20 0.41
EGFR P00533 1/20 0.40
FGFR1 P11362 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CDK1 P06493 1/20 0.39
CDC7 O00311 1/20 0.39
SYK P43405 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3279464 0.90 PDGFRB (0.45) JAK3PDGFRBPDGFRACDC7SYK
SCHEMBL3279915 0.90 PDGFRB (0.41) PDGFRBPDGFRAEGFRFGFR1CDC7
SCHEMBL3286379 0.87 EGFR (0.57) KDRJAK3PDGFRBPDGFRAEGFR
SCHEMBL3281003 0.87 PDGFRB (0.40) PDGFRBPDGFRAEGFRFGFR1CDC7
SCHEMBL3279022 0.85 KMT2A (0.44) KDRPDGFRBPDGFRAKDM4EALDH1A1
SCHEMBL3280195 0.85 PDGFRB (0.38) KDRPDGFRBPDGFRAEGFRFGFR1
SCHEMBL3286300 0.85 IKBKB (0.43) PDGFRBPDGFRA
SCHEMBL3285976 0.85 PDGFRB (0.50) PDGFRBPDGFRAEGFRFGFR1SYK
SCHEMBL3280387 0.84 SYK (0.58) PDGFRBPDGFRAEGFRFGFR1SYK
SCHEMBL13387117 0.78 EGFR (0.41) KDRJAK3PDGFRBPDGFRAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
WO-2009026107-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 WO disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK KDR 606/4885JAK1 4/4885JAK3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.